A randomised, parallel-group, open, controlled phase III trial assessing the treatment compliance with Grazax in subjects with seasonal grass pollen induced rhinoconjunctivitis

Trial Profile

A randomised, parallel-group, open, controlled phase III trial assessing the treatment compliance with Grazax in subjects with seasonal grass pollen induced rhinoconjunctivitis

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2012

At a glance

  • Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
  • Indications Grass pollen hypersensitivity; Rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors ALK-Abello
  • Most Recent Events

    • 29 Sep 2008 Actual end date (1 Oct 2007) added as reported by ClinicalTrials.gov.
    • 29 Sep 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 May 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top